<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117447</article-id><article-id pub-id-type="publisher-id">ACM-43891</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_94055200.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  脑梗死与肠道菌群关系的研究进展
  Research Progress on the Relationship between Cerebral Infarction and Intestinal Microbiome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>潇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>云财</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>亚军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>尹</surname><given-names>凤琼</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>昆明医科大学第二附属医院特需病房，云南 昆明</addr-line></aff><aff id="aff2"><addr-line>昆明医科大学，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3083</fpage><lpage>3090</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  肠道菌群在脑梗死(cerebral infraction, CI)中具有重要作用，与糖尿病、高脂血症、高血压、脑梗死的发生发展密切相关。胃肠道被称为第二大脑，其神经元数量仅次于中枢神经系统，胃肠道中微生物数量超过1014，是人类细胞数量的10倍，在人体健康中起着重要作用。本文将综述肠道菌群在糖尿病、高脂血症、高血压、脑梗死的发生、发展中的作用和机制，以及在脑梗死防治方面的潜在价值，为脑梗死的防治提供新思路。
   Intestinal microbiome plays an important role in cerebral infarction, and is closely related to the occurrence and development of diabetes, hyperlipidemia, hypertension and cerebral infarction. Gastrointestinal tract is known as the second brain, the number of neurons is second only to the central nervous system, the number of intestinal microbiome is more than 1014, which is 10 times the number of human cells, and plays an important role in human health. This article will review the role and mechanism of intestinal microbiome in the occurrence and development of diabetes, hyperlipidemia, hypertension and cerebral infarction, as well as its potential value in the prevention and treatment of cerebral infarction, so as to provide new ideas for the prevention and treatment of cerebral infarction.
 
</p></abstract><kwd-group><kwd>脑梗死，肠道菌群，糖尿病，高脂血症，高血压, Cerebral Infarction</kwd><kwd> Intestinal Microbiome</kwd><kwd> Diabetes</kwd><kwd> Hyperlipidemia</kwd><kwd> Hypertension</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肠道菌群在脑梗死(cerebral infraction, CI)中具有重要作用，与糖尿病、高脂血症、高血压、脑梗死的发生发展密切相关。胃肠道被称为第二大脑，其神经元数量仅次于中枢神经系统，胃肠道中微生物数量超过10<sup>14</sup>，是人类细胞数量的10倍，在人体健康中起着重要作用。本文将综述肠道菌群在糖尿病、高脂血症、高血压、脑梗死的发生、发展中的作用和机制，以及在脑梗死防治方面的潜在价值，为脑梗死的防治提供新思路。</p></sec><sec id="s2"><title>关键词</title><p>脑梗死，肠道菌群，糖尿病，高脂血症，高血压</p></sec><sec id="s3"><title>Research Progress on the Relationship between Cerebral Infarction and Intestinal Microbiome<sup> </sup></title><p>Xiao Yang<sup>1</sup>, Yuncai Liu<sup>1</sup>, Yajun Zhang<sup>1</sup>, Fengqiong Ying<sup>2*</sup></p><p><sup>1</sup>Kunming Medical University, Kunming Yunnan</p><p><sup>2</sup>Priority Ward, The Second Affiliated Hospital of Kunming Medical University, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/28-1572371x4_hanspub.png?20210716084127840" /></p><p>Received: Jun. 12<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/28-1572371x6_hanspub.png?20210716084127840" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Intestinal microbiome plays an important role in cerebral infarction, and is closely related to the occurrence and development of diabetes, hyperlipidemia, hypertension and cerebral infarction. Gastrointestinal tract is known as the second brain, the number of neurons is second only to the central nervous system, the number of intestinal microbiome is more than 10<sup>14</sup>, which is 10 times the number of human cells, and plays an important role in human health. This article will review the role and mechanism of intestinal microbiome in the occurrence and development of diabetes, hyperlipidemia, hypertension and cerebral infarction, as well as its potential value in the prevention and treatment of cerebral infarction, so as to provide new ideas for the prevention and treatment of cerebral infarction.</p><p>Keywords:Cerebral Infarction, Intestinal Microbiome, Diabetes, Hyperlipidemia, Hypertension</p><disp-formula id="hanspub.43891-formula13"><graphic xlink:href="//html.hanspub.org/file/28-1572371x7_hanspub.png?20210716084127840"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/28-1572371x8_hanspub.png?20210716084127840" /> <img src="//html.hanspub.org/file/28-1572371x9_hanspub.png?20210716084127840" /></p></sec><sec id="s5"><title>1. 引言</title><p>脑卒中是导致我国居民的首要死因。其中缺血型卒中占比69.6%~77.8%，而缺血性卒中主要原因是脑血栓的形成。缺血性卒中又称脑梗死，是指各种原因所致脑部血液供应障碍，导致局部脑缺血缺氧坏死，而出现相应功能缺损的一类临床综合征，脑血栓形成是缺血性脑卒中常见的类型，而动脉粥样硬化是脑学术形成的根本病因。在我国脑卒中发病率每年增加12%，而作为我国的主要劳动力35~64岁人口占比逐渐增加 [<xref ref-type="bibr" rid="hanspub.43891-ref1">1</xref>]，这显示脑卒中的发生越来越年轻化，这与糖尿病、高血压、肥胖的患病率上升有着密切关系 [<xref ref-type="bibr" rid="hanspub.43891-ref2">2</xref>]。这也表明缺血性脑卒中的防治对我国综合国力及人民的幸福生活等各方面都非常重要。</p><p>胃肠道又被称为第二大脑，因为其神经元数量仅次于中枢神经系统，其中的内分泌细胞，构成了人体最大的内分泌器官。人类胃肠道约250~400平方米，而胃肠道中微生物数量超过10<sup>14</sup>，其中细菌细胞的数量是人类细胞数量的10倍，而微生物基因组含量是人类基因组含量的100倍以上 [<xref ref-type="bibr" rid="hanspub.43891-ref3">3</xref>]，肠道菌群参与了一系列对宿主健康至关重要的生理过程，包括能量的稳定、代谢、神经行为发育、肠道上皮健康免疫活性等，其中某些功能是人体无法完成的代谢功能，所以胃肠道菌群又被称为携带人体“第二基因”的“隐形器官” [<xref ref-type="bibr" rid="hanspub.43891-ref4">4</xref>]。当肠道菌群组成与功能失衡时会引起与神经、呼吸、代谢、肝、心血管等疾病 [<xref ref-type="bibr" rid="hanspub.43891-ref5">5</xref>]。可见肠道菌群在人身体中发挥着重要作用。作者检索查询相关文献，通过对肠道菌群对糖尿病、高血压、高脂血症等的影响，进而旨在综述肠道菌群与缺血性脑卒的关系，为肠道菌群治疗及预防脑卒中提供参考。</p></sec><sec id="s6"><title>2. 肠道菌群与糖尿病之间的关系</title><p>肠道菌群主要从以下几个方面影响血糖的调控：肠降血糖素分泌，短链脂肪酸(short-chain fatty acid, SCFA)产生，胆汁酸代谢，脂肪组织调节。</p><sec id="s6_1"><title>2.1. 肠道菌群与肠降糖素</title><p>肠降血糖素是影响血糖控制的胃肠道肽物质，它基于一个假说：口服葡萄糖引起的胰岛素释放是静脉注射葡萄糖引起的葡萄糖释放的2~3倍。肠降糖激素包括：胰高血糖素样肽(glucagon-like peptide-1, GLP-1)、抑胃肽(gastric inhibitory polypeptide, GIP)等，它们通过刺激胰岛素B细胞，促进胰岛素的分泌，影响餐后血糖的降低。GLP-1和GIP分别由肠内分泌L细胞和K细胞分泌，L细胞在小肠远端的数量增加，而K细胞在小肠近端中含量最高，两种细胞类型均能感应肠腔碳水化合物 [<xref ref-type="bibr" rid="hanspub.43891-ref6">6</xref>]。GLP-1除能刺激胰岛素释放，还能增加胰岛素敏感性，促进胰岛B细胞复制，并保护其免受B细胞凋亡和细胞毒性攻击，抑制胰高血糖素的分泌，促进对胃排空 [<xref ref-type="bibr" rid="hanspub.43891-ref7">7</xref>]，另外对心肌有积极作用，还能改善认知和影响骨骼形成等 [<xref ref-type="bibr" rid="hanspub.43891-ref8">8</xref>]。且有研究表明糖尿病前期及诊断为2型糖尿病(diabetes mellitus, type 2, T2DM)患者的GLP-1反应较低 [<xref ref-type="bibr" rid="hanspub.43891-ref9">9</xref>]，其有可能成为糖尿病前期的诊断标准。在动物模型的研究中，发现肠道菌群失调会妨碍NO的生成，从而减少GLP-1的产生，婧儿而阻止了内脏脑向外周轴的有效激活，以控制胰岛素分泌和胃排空 [<xref ref-type="bibr" rid="hanspub.43891-ref7">7</xref>]。</p></sec><sec id="s6_2"><title>2.2. 肠道菌群与SCFA</title><p>SCFA的产生：短链脂肪酸主要包括乙酸，丙酸和丁酸，由肠道菌群通过对难消化的碳水化合物进行发酵而形成，它们除能为结肠细胞提供能量底物，还能减轻炎症反应，调节宿主饱腹感、血糖等。短链脂肪酸会刺激GLP-1的升高 [<xref ref-type="bibr" rid="hanspub.43891-ref10">10</xref>]。在我国进行的一项随机对照临床试验中，发现食物中增加不可消化但可发酵的碳水化合物的可诱导T2DM患者的临床相关代谢改善，并且可选择性促进一组产生乙酸和丁酸盐的菌株，这些菌群可能是维持肠道菌群和人体宿主之间的双向关系的关键角色，不仅对宿主有益，而且维持了肠道环境，使有害细菌远离。除此该实验将来自相同参与者的干预前和干预后肠道菌群移植到无菌小鼠体内，干预后小鼠代谢健康指标均优于干预前相应组移植的小鼠 [<xref ref-type="bibr" rid="hanspub.43891-ref11">11</xref>]。表明像T2DM这样的慢性疾病可能是肠道生态系统中有益功能减退或缺失的结果，并且通过个性化营养促进活性SCFA生产者成为维持肠道环境稳定的原因，这为控制肠道微生物群以治疗T2DM和其他潜在的与生物异常相关的疾病提供一种新的生态学方法。在日本的一项研究中，通过对主食的差异对比，研究其对肠道菌群组成和糖脂代谢的影响，结果显示：与吃精短粒白米7天相比，吃7天白面包显著提高了粪双歧杆菌、空腹GLP-1和呼吸氢的丰度，血浆SCFA也趋于升高 [<xref ref-type="bibr" rid="hanspub.43891-ref12">12</xref>]。这些研究表明通过食用富含不可消化但可发酵的碳水化合物，可增加血浆SCFA，进而改变机体的代谢，改善了血糖。</p></sec><sec id="s6_3"><title>2.3. 肠道菌群与胆汁酸代谢</title><p>胆汁酸的代谢：胆汁酸是肝细胞以胆固醇为原料，经过复杂的化学反应转变生成的24碳类胆固醇化合物，是胆固醇在体内主要代谢产物。进入肠道的各种胆汁酸约95%被肠壁重新吸收进入血液，经门静脉回到肝脏。胆汁酸具有较强的表面活性，能在油水界面降低表面张力，促进脂类乳化成细小微团，增加脂类与酯酶及肠壁的接触面积，促进脂类消化吸收，可防止胆结石的形成。胆汁酸在肝脏、肠道和外周组织中起信号分子的作用，通过激活相应受体调节代谢，如法尼酯衍生物X受体(farnesiod X recepter, FXR)和G蛋白偶联受体(G protein-coupled receptors, GPCRs)。肠道细菌可通过影响胆汁酸的代谢进而影响糖代谢其中FXR可调节胆汁酸内环境平衡和糖脂代谢，并可被初级胆汁酸和胆酸、次级胆汁酸和次级胆汁酸激活，与无菌小鼠相比，有细菌定殖的小鼠的胆汁酸水平降低 [<xref ref-type="bibr" rid="hanspub.43891-ref13">13</xref>]，表明肠道细菌可通过影响胆汁酸的代谢进而影响糖代谢。除此，在一项研究中，缩胆囊素介导的胆囊胆汁酸的排空可显著诱导GLP-1分泌 [<xref ref-type="bibr" rid="hanspub.43891-ref14">14</xref>]。另外，在德国的一项研究中，在用猪油和胆汁酸喂养的有细菌定殖的小鼠优势肠道细菌群落发生了变化，包括乳酸菌科的相对丰富度降低，脱硫弧菌科以及乳酸梭菌和丁酸梭菌增加，除此，用其肠道菌群定殖小鼠与无菌小鼠相比，定殖小鼠体内单不饱和脂肪酸和多不饱和脂肪酸的比例更高，且体重增加，胰岛素浓度较低，证明富含猪油和初级胆汁酸的饮食的有害代谢后果与宿主的微生物定殖有关 [<xref ref-type="bibr" rid="hanspub.43891-ref15">15</xref>]。同样通过对2型糖尿病病人经行药物降血糖，发现患者肠道微生物群中乳酸杆菌和双歧杆菌的相对丰度增加，而拟杆菌减少，以及增加患者中未结合粪胆汁酸的血浆水平，从而改善患者糖代谢 [<xref ref-type="bibr" rid="hanspub.43891-ref16">16</xref>]。</p></sec><sec id="s6_4"><title>2.4. 肠道菌群与脂肪组织的调节</title><p>脂肪组织的调节：脂肪组织包括白色脂肪和棕色脂肪，棕色脂肪是一种生热组织，通过调节脂肪分解代谢和上调能量消耗来帮助维持体重和体温，在成年人中的占比比较低，约0.5%，主要存在婴幼儿体内。在成人中，白色脂肪在全身脂肪组成中起主要作用，它将能量以脂肪的形式储存起来，并能释放多种细胞因子，这些细胞因子调节人体许多生理过程，包括脂代谢和炎症、胰岛素抵抗、2型糖尿病等 [<xref ref-type="bibr" rid="hanspub.43891-ref17">17</xref>]。在一项随机试验中，发现低聚果糖的菊糖的实验组较安慰剂对照组可以选择性地改变肠道微生物群，表现为肠道双歧杆菌数量及种类显著增加，而普通拟杆菌种类明显减少，实验组较对照组相比血清甘油三酯显著降低，超重或肥胖儿童的体重分数也显著降低 [<xref ref-type="bibr" rid="hanspub.43891-ref18">18</xref>]。通过对高拟杆菌比率组和低拟杆菌比率组全血和内脏脂肪组织的脱氧核糖核酸甲基化模式进行全基因组分析，发现高拟杆菌比率组血糖和HbA1c明显低于低拟杆菌组，除此，低拟杆菌比率组中葡萄糖和能量稳态的候选基因：组蛋白脱乙酰酶(histone deacetylase 7, HDAC7)和胰岛素样生长因子2-mRNA结合蛋白2 (recombinant insulin like growth factor 2 mRNA binding protein 2, IGF2BP2)相关基因均被甲基化并过表达，表示HDAC7和IGF2BP2的表达水平可以由肠道细菌表观遗传调控 [<xref ref-type="bibr" rid="hanspub.43891-ref19">19</xref>]。通过对瘦人和肥胖者的肠道菌群的研究，发现肥胖个体的谷氨酸发酵共生的拟杆菌的丰度明显降低，且与血清谷氨酸浓度呈负相关。通过用多形类杆菌进行管饲可降低血浆谷氨酸盐浓度并减轻，减轻饮食引起的小鼠体重增加和肥胖。同样通过减肥手术进行的减肥干预部分逆转了肥胖个体中与肥胖相关的微生物和代谢变化，包括多形类杆菌丰度的降低和血清谷氨酸浓度的升高，表明可以通过靶向肠道菌群来干预肥胖 [<xref ref-type="bibr" rid="hanspub.43891-ref20">20</xref>]。</p></sec></sec><sec id="s7"><title>3. 肠道菌群与高血压</title><p>高血压是脑梗死的重要危险因素之一，研究发现肠道菌群与高血压密切相关，与健康对照相比，发现高血压患者肠道微生物丰富度和多样性显著下降，与健康状态相关的细菌减少和普氏菌属和克雷伯氏菌属等细菌的过度生长。且发现，高血压前期组的微生物组特征与高血压组非常相似，表示高血压前期或高血压的宿主的代谢变化与肠道微生物组生态失调密切相关。此外，通过从高血压人供体到无菌小鼠的粪便移植，观察到血压升高可通过微生物群转移，并且证实了肠道微生物群对宿主血压的直接影响 [<xref ref-type="bibr" rid="hanspub.43891-ref21">21</xref>]。当正常大鼠植入自发性高血压性卒中易感性大鼠后，发现它的厚壁菌与拟杆菌之比增加，除此发现Adlercreutzia菌在正常小鼠菌群的丰度增加，它能将茶素没食子酸酯(epigallocatechin gallate, EGCG)代谢为可抑制血管紧张素I转化酶，增加内皮NO产生并降低血压的代谢物 [<xref ref-type="bibr" rid="hanspub.43891-ref22">22</xref>]。另一实验发现，硫酸脱磷孤菌属在收缩期高血压患者中增加，而硫酸脱磷孤菌属可以减少硫化氢，它能抑制上皮细胞对丁酸盐氧化，丁酸盐是上皮细胞的主要能量来源，这种代谢造成的血管上皮细胞改变是细菌引起高血压的潜在机制 [<xref ref-type="bibr" rid="hanspub.43891-ref23">23</xref>]。</p></sec><sec id="s8"><title>4. 肠道菌群与高脂血症</title><p>肠道菌群影响着血脂的吸收，如肠道双歧杆菌和乳酸菌比重大，大肠杆菌少时，血脂低。脂蛋白E是除低密度脂蛋白(low-density lipoprotein, LDL)外的所有脂蛋白的组成部分，是肝脏LDL受体和低密度脂蛋白受体相关蛋白(low-density lipoprotein receptor related protein, LRP)的配体，在乳糜微粒残体和极低密度脂蛋白的分解代谢中起重要作用。脂蛋白E基因的遗传缺陷导致了人和动物血浆中富含胆固醇残体的积累，通过对在西方饮食的脂蛋白E基因敲除的小鼠中与正常野生小鼠的试验，脂蛋白E基因敲除的小鼠中发现厚壁菌门和梭状芽胞杆菌均有富集 [<xref ref-type="bibr" rid="hanspub.43891-ref24">24</xref>]，而厚壁菌门的相对丰富可导致脂多糖等代谢内毒素的增加 [<xref ref-type="bibr" rid="hanspub.43891-ref25">25</xref>]。在梭状芽孢杆菌科中，包括天冬酰胺型梭状芽孢杆菌、哈德威梭状芽孢杆菌和产孢梭状芽孢杆菌在内的三个物种也被报道与三甲胺n-氧化物(trimethylamine N-oxide, TMAO)的积累有关 [<xref ref-type="bibr" rid="hanspub.43891-ref26">26</xref>]。</p></sec><sec id="s9"><title>5. 肠道菌群与脑梗死</title><p>肠道菌群与大脑之间有着密切的联系，大脑影响着肠道的功能，肠道也与大脑的发育、功能及神经系统疾病等相关，除此还与多种疾病有关，如自闭症、抑郁、焦虑和精神分裂症等，实际上肠道菌群与宿主保持着一种长期共同生长相互影响的共生的关系 [<xref ref-type="bibr" rid="hanspub.43891-ref27">27</xref>]，我们称之为双向肠–脑轴。脑肠轴的主要组成部分包括脊髓丘脑束的感觉纤维，迷走神经的副交感神经纤维，以及中枢神经系统与内分泌系统交界的下丘脑–垂体轴。</p><sec id="s9_1"><title>5.1. 肠道菌群影响动脉粥样硬化的形成</title><p>动脉粥样硬化与肠道菌群之间也有着密切的关系，如肠道菌群参与形成的三甲胺氧化物在心血管动脉粥样硬化中起着重要作用。TMAO是一种影响血小板反应性和血栓形成潜力的致动脉粥样硬化代谢物，它可阻断胆固醇运输和改变胆汁酸组成来加速动脉粥样硬化，激活血小板促进血栓形成，并影响心脏不良重塑来增加高血压导致的心力衰竭。TMAO水平升高的人发生重大不良心血管事件风险增加 [<xref ref-type="bibr" rid="hanspub.43891-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.43891-ref29">29</xref>]。当人体摄入富含三甲氧基苯异丙胺(tri-methoxy amphetamine, TMA)的食物，如胆碱，磷脂酰胆碱和肉毒碱，肠道菌群通过自身的TMA裂解酶将这些食物转换为TMA，然后通过肠道吸收血液循环到达肝脏，通过肝黄素单加氧酶3 (flavin monooxygenase 3, FMO3)代谢，最终转换为TMAO，再重新进入血液循环到达全身组织 [<xref ref-type="bibr" rid="hanspub.43891-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.43891-ref31">31</xref>]。</p><p>曾有实验评估TMAO浓度与首次中风风险的关系。通过检测氧化三甲胺浓度与中国高血压人群首次中风风险之间的关联，证实较高的TMAO水平将导致首次卒中风险增加 [<xref ref-type="bibr" rid="hanspub.43891-ref29">29</xref>]。空腹血浆TMAO水平成为冠心病患者动脉粥样硬化高负荷的独立预测因子，较高的TMAO可以预测动脉粥样硬化负担和复杂性的增加 [<xref ref-type="bibr" rid="hanspub.43891-ref32">32</xref>]。且另一个研究中也证实了TMAO与肠道菌群之间的关系，即饮食中磷脂酰胆碱产生的TMAO依赖于肠道微生物群的代谢，并通过数据证明TMAO水平升高与主要不良心血管事件发生风险增加有关 [<xref ref-type="bibr" rid="hanspub.43891-ref33">33</xref>]。</p></sec><sec id="s9_2"><title>5.2. 脑卒中影响肠道菌群的改变</title><p>菌群的改变也影响着脑卒中的预后 [<xref ref-type="bibr" rid="hanspub.43891-ref34">34</xref>]。有研究发现，以动脉粥样硬化脑卒中和短暂性脑缺血发作为患者组与正常人的对照组对比，发现患者组主要有3个主要贫化属，即拟杆菌属、普氏杆菌属和粪肠杆菌属，它们是肠道主要的共生菌或有益菌，另外，患者组较对照组中肠道致病菌增加 [<xref ref-type="bibr" rid="hanspub.43891-ref35">35</xref>]。在一个实验中，幼小鼠实验性中风后微生物群发生了改变，类似于未受损伤的老年小鼠的生物群落。正常老年小鼠与正常年轻小鼠相比，肠道微生物群中两种主要细菌门：厚壁菌门与拟杆菌门的比例增加了约9倍。老年小鼠中这种增加的厚壁菌门：拟杆菌门比率表明生态失调。通过粪便强饲法改变年轻小鼠的微生物群，使其与老年小鼠相似，则大脑中动脉闭塞后死亡率增加，行为测试表现降低，细胞因子水平增加。相反，如改变老年人的微生物群并使其类似于年轻小鼠的微生物群，则大脑中动脉闭塞后存活率提高，恢复得更好。这表明老年生物群系增加了系统性促炎细胞因子的水平 [<xref ref-type="bibr" rid="hanspub.43891-ref36">36</xref>]。</p></sec><sec id="s9_3"><title>5.3. 肠道菌群影响卒中预后</title><sec id="s9_3_1"><title>5.3.1. 抗炎作用</title><p>脑卒中会引发神经炎症反应，包括脑内小胶质细胞的激活和白细胞的侵袭。这些影响主要是通过T细胞介导引起的神经炎症，其中促炎细胞因子表达的转录调控与小胶质激活IL-1β和Tnf-α等有关 [<xref ref-type="bibr" rid="hanspub.43891-ref37">37</xref>]。除此发现肠道菌群对卒中具有保护作用。一个研究发现，与定殖的同窝或传统饲养的无特殊定殖菌级小鼠相比，发现肠道菌群的完全缺失的小鼠卒中后脑损伤扩大，表明肠道菌群的缺失是有害的。通过比较无菌小鼠与重新定殖细菌的无菌小鼠相比，细菌定殖增加了大脑中细胞因子的表达以及小胶质细胞计数。淋巴细胞缺陷小鼠中不存在微生物组介导的脑保护作用。当促炎细胞亚群(如Th1、Th17)促进神经炎症时，其他具有抗炎特性的细胞群(如Treg细胞)可能具有脑保护作用 [<xref ref-type="bibr" rid="hanspub.43891-ref34">34</xref>]。</p></sec><sec id="s9_3_2"><title>5.3.2. 改善肠道粘膜屏障</title><p>SCFAs也是肠道菌群影响卒中结果的重要物质，一项研究发现卒中会造成血液SCFAs浓度降低，而SCFAs可以通过调节入侵大脑的淋巴细胞对小胶质细胞功能的影响来改善卒中后恢复，并通过增加食物中SCFAs含量，改善了卒中后症状，并检测到脾脏中系统T细胞计数显著减少，脾脏是一个次级淋巴器官，它可以反映卒中后的系统免疫反应 [<xref ref-type="bibr" rid="hanspub.43891-ref38">38</xref>]。丁酸盐是SCFAs的一种，它是肠道上皮细胞的优先能量来源，它能保护上皮的健康。丁酸盐也会影响嗜粘蛋白–艾克曼菌在上皮细胞中引起的基因表达水平。艾克曼菌可能通过促进丁酸盐水平，在创伤损伤的愈合中发挥关键作用，从而巩固卒中后小鼠的肠道上皮的完整性。此外，嗜粘蛋白–艾克曼菌可能诱发结肠粘液生产和表达Reg3γ，导致微生物群重构 [<xref ref-type="bibr" rid="hanspub.43891-ref39">39</xref>]。另一研究也表明通过移植富含SCFAs的粪便菌干扰肠道菌群来补充丁酸是治疗缺血性脑卒中的有效方法 [<xref ref-type="bibr" rid="hanspub.43891-ref40">40</xref>]。</p></sec><sec id="s9_3_3"><title>5.3.3. 大脑与肠道之间的信号传导</title><p>脑组织在受到一定强度的刺激作用下，机体产生应激信号，由大脑传递到胃肠道，主要通过两条途径，交感–肾上腺髓质系统和下丘脑–垂体–肾上腺皮质轴，导致组织微环境的失衡，诱发生理功能状态的变化，最终造成损伤的出现 [<xref ref-type="bibr" rid="hanspub.43891-ref41">41</xref>]。当激活促肾上腺皮质激素释放激素的I型受体时，它能通过促进肠道炎症、增加肠道通透性、改变肠道形态、调节肠道菌群来引起肠道损伤。促肾上腺皮质激素释放激素除影响肾上腺素的分泌，还影响肠道细胞的活动，如免疫细胞、上皮细胞、肠神经元和平滑肌细胞1类固醇还会增加肠道的通透性 [<xref ref-type="bibr" rid="hanspub.43891-ref42">42</xref>]。当胃肠道屏障作用下降后，宿主肠道微生物群到外周组织的选择性细菌移位导致卒中后感染 [<xref ref-type="bibr" rid="hanspub.43891-ref43">43</xref>]。暗示肠上皮粘膜和肠道菌群是脑卒中后死亡率增加的主要因素。</p></sec></sec></sec><sec id="s10"><title>6. 结论</title><p>最近几年，人们逐渐加强了肠道菌群对人体健康影响的意识，肠道菌群与脑卒中的研究相关的研究也越来越多。目前的证据提示肠道菌群对脑卒中的发生发展都有千丝万缕的联系，但具体通过干扰肠道菌群来进行对卒中的预防及治疗的效果还有待进一步研究。</p></sec><sec id="s11"><title>文章引用</title><p>杨 潇,刘云财,张亚军,尹凤琼. 脑梗死与肠道菌群关系的研究进展Research Progress on the Relationship between Cerebral Infarction and Intestinal Microbiome[J]. 临床医学进展, 2021, 11(07): 3083-3090. https://doi.org/10.12677/ACM.2021.117447</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43891-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Jiang, B., Sun, H., Ru, X., Sun, D., Wang, L., et al. (2017) Prevalence, Incidence, and Mortality of Stroke in China. Circulation, 135, 759-771. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.116.025250</mixed-citation></ref><ref id="hanspub.43891-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ning, X., Sun, J., Jiang, R., Lu, H., Bai, L., Shi, M., et al. (2017) Increased Stroke Burdens Among the Low-Income Young and Middle Aged in Rural China. Stroke, 48, 77-83. &lt;br&gt;https://doi.org/10.1161/strokeaha.116.014897</mixed-citation></ref><ref id="hanspub.43891-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bäckhed, F., Ley, R.E., Sonnenburg, J.L., Peterson, D.A. and Gordon, J.I. (2005) Host-Bacterial Mutualism in the Human Intestine. Science, 307, 1915-1920. &lt;br&gt;https://doi.org/10.1126/science.1104816</mixed-citation></ref><ref id="hanspub.43891-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Barko, P.C., Mcmichael, M.A., Swanson, K.S. and Williams, D. (2018) The Gastrointestinal Microbiome: A Review. Journal of Veterinary Internal Medicine, 32, 9-25. &lt;br&gt;https://doi.org/10.1111/jvim.14875</mixed-citation></ref><ref id="hanspub.43891-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lynch, S.V. and Pedersen, O. (2016) The Human Intestinal Microbiome in Health and Disease. The New England Journal of Medicine, 375, 2369-2379. &lt;br&gt;https://doi.org/10.1056/nejmra1600266</mixed-citation></ref><ref id="hanspub.43891-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Reimann, F. and Gribble, F.M. (2016) Mechanisms Underlying Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Secretion. Journal of Diabetes Investigation, 7, 13-19. &lt;br&gt;https://doi.org/10.1111/jdi.12478</mixed-citation></ref><ref id="hanspub.43891-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J.E., Tercé, F., et al. (2017) A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metabolism, 26, 278. &lt;br&gt;https://doi.org/10.1016/j.cmet.2017.06.003</mixed-citation></ref><ref id="hanspub.43891-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ankit, G., Jelinek, H.F. and Hayder, A.-A. (2017) Glucagon Like Peptide-1 and Its Receptor Agonists: Their Roles in Management of Type 2 Diabetes Mellitus. Diabetes &amp; Metabolic Syndrome, 11, 225-230.  
&lt;br&gt;https://doi.org/10.1016/j.dsx.2016.09.003</mixed-citation></ref><ref id="hanspub.43891-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Færch, K., Torekov, S.S., Vistisen, D., Johansen, N.B., Witte, D.R., Jonsson, A., et al. (2015) GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes, 64, 2513-2525. &lt;br&gt;https://doi.org/10.2337/db14-1751</mixed-citation></ref><ref id="hanspub.43891-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Psichas, A., Sleeth, M.L., Murphy, K.G., Brooks, L., Bewick, G.A., Hanyaloglu, A.C., et al. (2015) The Short Chain Fatty Acid Propionate Stimulates GLP-1 and PYY Secretion via Free Fatty Acid Receptor 2 in Rodents. International Journal of Obesity, 39, 424-429. &lt;br&gt;https://doi.org/10.1038/ijo.2014.153</mixed-citation></ref><ref id="hanspub.43891-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y.Y., Wang, X., et al. (2018) Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2 Diabetes. Science, 359, 1151-1156. &lt;br&gt;https://doi.org/10.1126/science.aao5774</mixed-citation></ref><ref id="hanspub.43891-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mano, F., Ikeda, K., Joo, E., Fujita, Y., Yamane, S., Harada, N., et al. (2018) The Effect of White Rice and White Bread as Staple Foods on Gut Microbiota and Host Metabolism. Nutrients, 10, Article No. 1323.  
&lt;br&gt;https://doi.org/10.3390/nu10091323</mixed-citation></ref><ref id="hanspub.43891-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Annika, W., Petia, K.-D., Marcus, S., Bäckhed, F. and Marschall, H.-U. (2017) Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling. Digestive Diseases, 35, 246-250.  
&lt;br&gt;https://doi.org/10.1159/000450982</mixed-citation></ref><ref id="hanspub.43891-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Brønden, A., Albér, A., Rohde, U., Gasbjerg, L.S., Rehfeld, J.F., Holst, J.J., et al. (2018) The Bile Acid-Sequestering Resin Sevelamer Eliminates the Acute GLP-1 Stimulatory Effect of Endogenously Released Bile Acids in Patients with Type 2 Diabetes. Diabetes, Obesity &amp; Metabolism, 20, 362-369. &lt;br&gt;https://doi.org/10.1111/dom.13080</mixed-citation></ref><ref id="hanspub.43891-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Just, S., Mondot, S., Ecker, J., Wegner, K., Rath, E., Gau, L., et al. (2018) The Gut Microbiota Drives the Impact of Bile Acids and Fat Source in Diet on Mouse Metabolism. Microbiome, 6, Article No. 134.  
&lt;br&gt;https://doi.org/10.1186/s40168-018-0510-8</mixed-citation></ref><ref id="hanspub.43891-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Yanyun, G., Xiaokai, W., Junhua, L., Zhang, Y., Zhong, H., Liu, R., et al. (2017) Analyses of Gut Microbiota and Plasma Bile Acids Enable Stratification of Patients for Antidiabetic Treatment. Nature Communications, 8, Article No. 1785. &lt;br&gt;https://doi.org/10.1038/s41467-017-01682-2</mixed-citation></ref><ref id="hanspub.43891-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rong, B., Xia, T., Zhang, T., Feng, R., Huang, H., Wu, Q., et al. (2019) Gut Microbiota: A Potential Manipulator for Host Adipose Tissue and Energy Metabolism. The Journal of Nutritional Biochemistry, 64, 206-217.  
&lt;br&gt;https://doi.org/10.1016/j.jnutbio.2018.10.020</mixed-citation></ref><ref id="hanspub.43891-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nicolucci, A.C., Hume, M.P., Martínez, I., Mayengbam, S., Walter, J. and Reimer, R.A. (2017) Prebiotics Reduce Body Fat and Alter Intestinal Microbiota in Children Who Are Overweight or with Obesity. Gastroenterology, 153, 711-722. &lt;br&gt;https://doi.org/10.1053/j.gastro.2017.05.055</mixed-citation></ref><ref id="hanspub.43891-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ramos-Molina, B., Sánchez-Alcoholado, L., Cabrera-Mulero, A., Lopez-Dominguez, R., Carmona-Saez, P., Garcia-Fuentes, E., et al. (2019) Gut Microbiota Composition Is Associated with the Global DNA Methylation Pattern in Obesity. Frontiers in Genetics, 10, Article No. 613. &lt;br&gt;https://doi.org/10.3389/fgene.2019.00613</mixed-citation></ref><ref id="hanspub.43891-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y., et al. (2017) Gut Microbiome and Serum Metabolome Alterations in Obesity and after Weight-Loss Intervention. Nature Medicine, 23, 859-868. &lt;br&gt;https://doi.org/10.1038/nm.4358</mixed-citation></ref><ref id="hanspub.43891-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Zhao, F., Wang, Y., Chen, J., Tao, J., Tian, G., et al. (2017) Gut Microbiota Dysbiosis Contributes to the Development of Hypertension. Microbiome, 5, Article No. 14. &lt;br&gt;https://doi.org/10.1186/s40168-016-0222-x</mixed-citation></ref><ref id="hanspub.43891-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Adnan, S., Nelson, J.W., Ajami, N.J., Venna, V.R., Petrosino, J.F., Bryan Jr., R.M., et al. (2017) Alterations in the Gut Microbiota Can Elicit Hypertension in Rats. Physiological Genomics, 49, 96-104.  
&lt;br&gt;https://doi.org/10.1152/physiolgenomics.00081.2016</mixed-citation></ref><ref id="hanspub.43891-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Xie, D., Zhang, M., Wang, B., Lin, H., Wu, E., Zhao, H., et al. (2019) Differential Analysis of Hypertension-Associated Intestinal Microbiota. International Journal of Medical Sciences, 16, 872-881. &lt;br&gt;https://doi.org/10.7150/ijms.29322</mixed-citation></ref><ref id="hanspub.43891-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Zhang, Y., Wang, R., An, Y., Gao, W., Bai, L., et al. (2018) Western Diet Feeding Influences Gut Microbiota Profiles in apoE Knockout Mice. Lipids in Health and Disease, 17, Article No. 159.  
&lt;br&gt;https://doi.org/10.1186/s12944-018-0811-8</mixed-citation></ref><ref id="hanspub.43891-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Poppleton, D.I., Duchateau, M., Hourdel, V., Matondo, M., Flechsler, J., Klingl, A., et al. (2017) Outer Membrane Proteome of Veillonella parvula: A Diderm Firmicute of the Human Microbiome. Frontiers in Microbiology, 8, Article No. 1215. &lt;br&gt;https://doi.org/10.3389/fmicb.2017.01215</mixed-citation></ref><ref id="hanspub.43891-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Romano, K.A., Vivas, E.I., Amador-Noguez, D. and Rey, F.E. (2015) Intestinal Microbiota Composition Modulates Choline Bioavailability from Diet and Accumulation of the Proatherogenic Metabolite Trimethylamine-N-Oxide. mBio, 6, e02481. &lt;br&gt;https://doi.org/10.1128/mBio.02481-14</mixed-citation></ref><ref id="hanspub.43891-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., D’Souza, R. and Hong, S.-T. (2013) The Role of Gut Microbiota in the Gut-Brain Axis: Current Challenges and Perspectives. Protein &amp; Cell, 4, 403-414. &lt;br&gt;https://doi.org/10.1007/s13238-013-3017-x</mixed-citation></ref><ref id="hanspub.43891-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, W., Buffa, J.A., Wang, Z., Warrier, M., Schugar, R., Shih, D.M., et al. (2018) Flavin Monooxygenase 3, the Host Hepatic Enzyme in the Metaorganismal Trimethylamine N-Oxide-Generating Pathway, Modulates Platelet Responsiveness and Thrombosis Risk. Journal of Thrombosis and Haemostasis, 16, 1857-1872.  
&lt;br&gt;https://doi.org/10.1111/jth.14234</mixed-citation></ref><ref id="hanspub.43891-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Nie, J., Xie, L., Zhao, B.X., Li, Y., Qiu, B., Zhu, F., et al. (2018) Serum Trimethylamine N-Oxide Concentration Is Positively Associated with First Stroke in Hypertensive Patients. Stroke, 49, 2021-2028.  
&lt;br&gt;https://doi.org/10.1161/strokeaha.118.021997</mixed-citation></ref><ref id="hanspub.43891-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., DuGar, B., et al. (2011) Gut Flora Metabolism of Phosphatidylcholine Promotes Cardiovascular Disease. Nature, 472, 57-63. &lt;br&gt;https://doi.org/10.1038/nature09922</mixed-citation></ref><ref id="hanspub.43891-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Koeth, R.A., Levison, B.S., Culley, M.K., Buffa, J.A., Wang, Z., Gregory, J.C., et al. (2014) γ-Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAO. Cell Metabolism, 20, 799-812.  
&lt;br&gt;https://doi.org/10.1016/j.cmet.2014.10.006</mixed-citation></ref><ref id="hanspub.43891-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Senthong, V., Li, X.S., Hudec, T., Coughlin, J., Wu, Y., Levison, B., et al. (2016) Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated with Atherosclerotic Burden. Journal of the American College of Cardiology, 67, 2620-2628. &lt;br&gt;https://doi.org/10.1016/j.jacc.2016.03.546</mixed-citation></ref><ref id="hanspub.43891-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Tang, W.H., Wang, Z. and Levison, B.S. (2013) Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. Journal of Vascular Surgery, 58, 549. &lt;br&gt;https://doi.org/10.1016/j.jvs.2013.06.007</mixed-citation></ref><ref id="hanspub.43891-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Singh, V., Sadler, R., Heindl, S., Llovera, G., Roth, S., Benakis, C., et al. (2018) The Gut Microbiome primes a Cerebroprotective Immune Response after Stroke. Journal of Cerebral Blood Flow &amp; Metabolism, 38, 1293-1298.  
&lt;br&gt;https://doi.org/10.1177/0271678X18780130</mixed-citation></ref><ref id="hanspub.43891-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Yin, J., Liao, S.X., He, Y., Wang, S., Xia, G.H., Liu, F.T., et al. (2015) Dysbiosis of Gut Microbiota with Reduced Trimethylamine-N-Oxide Level in Patients with Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. Journal of the American Heart Association, 4, e002699. &lt;br&gt;https://doi.org/10.1161/JAHA.115.002699</mixed-citation></ref><ref id="hanspub.43891-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Spychala, M.S., Venna, V.R., Jandzinski, M., Doran, S.J., Durgan, D.J., Ganesh, B.P., et al. (2018) Age-Related Changes in the Gut Microbiota Influence Systemic inflammation and stroke outcome. Annals of Neurology, 84, 23-36.  
&lt;br&gt;https://doi.org/10.1002/ana.25250</mixed-citation></ref><ref id="hanspub.43891-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Vikramjeet, S., Stefan, R., Gemma, L., Sadler, R., Garzetti, D., Stecher, B., et al. (2016) Microbiota Dysbiosis Controls the Neuroinflammatory Response after Stroke. The Journal of Neuroscienc, 36, 7428-7440.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.1114-16.2016</mixed-citation></ref><ref id="hanspub.43891-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Sadler, R. and Liesz, A. (2020). Short-Chain Fatty Acids Improve Poststroke Recovery via Immunological Mechanisms. Journal of Neuroscience, 40, 1162-1173. &lt;br&gt;https://doi.org/10.1523/JNEUROSCI.1359-19.2019</mixed-citation></ref><ref id="hanspub.43891-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Koh, A., Vadder, F.D., Kovatcheva-Datchary, P. and Bäckhe, F. (2016) From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell, 165, 1332-1345. &lt;br&gt;https://doi.org/10.1016/j.cell.2016.05.041</mixed-citation></ref><ref id="hanspub.43891-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Chen, R., Xu, Y., Wu, P., Zhou, H., Lasanajak, Y., Fang, Y., et al. (2019) Transplantation of Fecal Microbiota Rich in Short Chain Fatty Acids and Butyric Acid Treat Cerebral Ischemic Stroke by Regulating Gut Microbiota. Pharmacological Research, 148, Article ID: 104403. &lt;br&gt;https://doi.org/10.1016/j.phrs.2019.104403</mixed-citation></ref><ref id="hanspub.43891-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">胡诗浩, 杨旭萍, 刘佩芳, 黄寅. 脑卒中并发应激性溃疡的研究进展[J]. 中国医药科学, 2019, 9(16): 47-50+135.</mixed-citation></ref><ref id="hanspub.43891-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Li, B., Lee, C., Filler, T., Hock, A., Wu, R.Y., Li, Q., et al. (2017) Inhibition of Corticotropin-Releasing Hormone Receptor 1 and Activation of Receptor 2 Protect against Colonic Injury and Promote Epithelium Repair. Scientific Reports, 7, Article No. 46616. &lt;br&gt;https://doi.org/10.1038/srep46616</mixed-citation></ref><ref id="hanspub.43891-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Stanley, D., Mason, L.J., Mackin, K.E., Srikhanta, Y.N, Lyras, D., Prakash, M.D, et al. (2016) Translocation and Dissemination of Commensal Bacteria in Post-Stroke Infection. Nature Medicine, 22, 1277-1284.  
&lt;br&gt;https://doi.org/10.1038/nm.4194</mixed-citation></ref></ref-list></back></article>